JP2011529921A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529921A5 JP2011529921A5 JP2011521364A JP2011521364A JP2011529921A5 JP 2011529921 A5 JP2011529921 A5 JP 2011529921A5 JP 2011521364 A JP2011521364 A JP 2011521364A JP 2011521364 A JP2011521364 A JP 2011521364A JP 2011529921 A5 JP2011529921 A5 JP 2011529921A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- item
- cycloalkyl
- compound
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 114
- 229910052739 hydrogen Inorganic materials 0.000 claims description 58
- 239000001257 hydrogen Substances 0.000 claims description 56
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 46
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 32
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 125000001072 heteroaryl group Chemical group 0.000 claims description 30
- 125000003342 alkenyl group Chemical group 0.000 claims description 27
- 125000000304 alkynyl group Chemical group 0.000 claims description 27
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 27
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 27
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 27
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 27
- 150000001413 amino acids Chemical group 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000012453 solvate Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- -1 R 21 Chemical compound 0.000 claims description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 5
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 5
- 125000001188 haloalkyl group Chemical group 0.000 claims description 5
- 125000001475 halogen functional group Chemical group 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 229960000310 isoleucine Drugs 0.000 claims description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 5
- 125000004001 thioalkyl group Chemical group 0.000 claims description 5
- 150000003573 thiols Chemical class 0.000 claims description 5
- 239000004474 valine Chemical group 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- YELDUWMYYRJMJD-UHFFFAOYSA-N 2-sulfamoylguanidine Chemical compound NC(N)=NS(N)(=O)=O YELDUWMYYRJMJD-UHFFFAOYSA-N 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 3
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims description 3
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 3
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000001243 protein synthesis Methods 0.000 claims description 2
- 230000014616 translation Effects 0.000 claims description 2
- 101100240527 Caenorhabditis elegans nhr-22 gene Proteins 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 101150024084 nhr-28 gene Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 82
- 229940024606 amino acid Drugs 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 125000000547 substituted alkyl group Chemical group 0.000 description 12
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 241000700605 Viruses Species 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- CEUKVIUTWQHCJM-UHFFFAOYSA-N CSCCC(CS(O)(=O)=O)NC(CN)=O Chemical compound CSCCC(CS(O)(=O)=O)NC(CN)=O CEUKVIUTWQHCJM-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8555608P | 2008-08-01 | 2008-08-01 | |
| US61/085,556 | 2008-08-01 | ||
| PCT/US2009/052474 WO2010014943A2 (en) | 2008-08-01 | 2009-07-31 | Methionine analogs and methods of using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011529921A JP2011529921A (ja) | 2011-12-15 |
| JP2011529921A5 true JP2011529921A5 (https=) | 2012-09-13 |
| JP5650642B2 JP5650642B2 (ja) | 2015-01-07 |
Family
ID=41414372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521364A Expired - Fee Related JP5650642B2 (ja) | 2008-08-01 | 2009-07-31 | メチオニンアナログおよびそれらを使用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US8580859B2 (https=) |
| EP (1) | EP2326619B1 (https=) |
| JP (1) | JP5650642B2 (https=) |
| CN (1) | CN102171185A (https=) |
| AU (1) | AU2009276343A1 (https=) |
| CA (1) | CA2733390A1 (https=) |
| IL (1) | IL210956A0 (https=) |
| WO (1) | WO2010014943A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2326619B1 (en) | 2008-08-01 | 2019-02-27 | Bioxiness Pharmaceuticals, Inc. | Methionine analogs and methods of using same |
| US9200251B1 (en) | 2011-03-31 | 2015-12-01 | David Gordon Bermudes | Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith |
| WO2019169029A1 (en) | 2018-02-28 | 2019-09-06 | Bioxiness Pharmaceuticals, Inc. | Target specific chemotherapeutic agents |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR961832A (https=) * | 1943-03-20 | 1950-05-23 | ||
| CH254537A (de) | 1947-12-18 | 1948-05-15 | Ag Sandoz | Verfahren zur Herstellung eines neuen kapillaraktiven Stoffes. |
| DE1020144B (de) * | 1956-07-02 | 1957-11-28 | Dehydag Gmbh | Wasch- und Reinigungsmittel |
| FR1390191A (fr) | 1963-07-19 | 1965-02-26 | Dehydag Gmbh | Procédé de préparation de sulfobétaïnes à bases hétérocycliques de type aromatique |
| US3519683A (en) * | 1967-03-31 | 1970-07-07 | Meiji Seika Co | Process for preparing 5-amino-5-deoxy-d-glucose-1-sulfonic acid |
| GB1580899A (en) | 1976-07-27 | 1980-12-10 | Fujisawa Pharmaceutical Co | Hydroxyaminohydrocarbonphosphonic acid derivatives and production and use thereof |
| JPS5463024A (en) | 1977-10-27 | 1979-05-21 | Fujisawa Pharmaceut Co Ltd | 3-(n-formyl-n-hydroxyamino)-2(r)-hydroxypropyl-phosphonic acid, its preparation, and its use |
| US4169950A (en) * | 1977-12-08 | 1979-10-02 | Research Organics | Amino-hydroxy-alkyl sulfonic acid zwitterions |
| IL61985A0 (en) | 1980-02-01 | 1981-02-27 | Sparamedica Ag | Phosphinic and phosphonic acid derivatives,their manufacture and pharmaceutical compositions containing them |
| ATE22565T1 (de) | 1981-11-02 | 1986-10-15 | Ici Plc | Substituierte propylphosphonsaeurederivate, ihre verwendung als herbizide, sie enthaltende herbizide zusammensetzungen und verfahren zu ihrer herstellung. |
| DE3245887A1 (de) * | 1982-12-11 | 1984-06-14 | Degussa Ag, 6000 Frankfurt | Verfahren zur herstellung substituierter phosphon und phosphinsaeuren |
| GB8308506D0 (en) | 1983-03-28 | 1983-05-05 | Ici Plc | Heterocyclic compounds |
| GB8410989D0 (en) | 1984-04-30 | 1984-06-06 | Ici Plc | Heterocyclic compounds |
| DE3435156A1 (de) | 1984-09-25 | 1986-04-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur herstellung der stereoisomeren von 1-amino-alkylphosphonsaeuren oder 1-aminoalkylphosphinsaeuren |
| JPS62215597A (ja) | 1986-03-14 | 1987-09-22 | Mitsubishi Chem Ind Ltd | β−メルカプト−α−アミノエチルホスホン酸誘導体 |
| IT1211792B (it) | 1987-09-21 | 1989-11-03 | Sigma Tau Ind Farmaceuti | O-alcanoil derivati dell'acido 3ammino-2-idrossipropansolfonico adattivita'anticonvulsivante e loro composizioni farmaceutiche per il trattamento terapeutico dell'epilessia |
| GB8727792D0 (en) | 1987-11-27 | 1987-12-31 | Merck Sharp & Dohme | Therapeutic agents |
| SE8801729D0 (sv) | 1988-05-06 | 1988-05-06 | Astra Ab | Purine derivatives for use in therapy |
| JP2733511B2 (ja) | 1988-10-22 | 1998-03-30 | 日本臓器製薬株式会社 | 新規アミノアルカン誘導体 |
| JP3174566B2 (ja) | 1990-04-20 | 2001-06-11 | 日本臓器製薬株式会社 | アミノアルカン誘導体 |
| JP2724906B2 (ja) | 1990-07-19 | 1998-03-09 | 日本臓器製薬株式会社 | 新規フェニルアラニルアミノアルカン誘導体 |
| EP0467856B1 (en) * | 1990-07-19 | 1997-03-19 | Nippon Zoki Pharmaceutical Co. Ltd. | Aminoalkanesulfonic acid derivatives and pharmaceutical compositions for use in preventing or treating heart diseases |
| DE4124004C2 (de) | 1991-07-19 | 1995-01-26 | Hell Ag Linotype | Vorrichtung zum Auf- und Abspannen von Filmmaterial und Betriebsweise der Vorrichtung |
| GB9122859D0 (en) * | 1991-10-28 | 1991-12-11 | Smithkline Beecham Plc | Novel compounds |
| JPH07116382B2 (ja) | 1992-01-28 | 1995-12-13 | 株式会社同仁化学研究所 | 水溶性メチレンビスジアルキルアニリン誘導体及びその塩類並びにそれらを用いた過酸化物質定量用組成物 |
| GB9202779D0 (en) | 1992-02-10 | 1992-03-25 | Ici Plc | Novel compounds |
| US5760021A (en) * | 1992-05-29 | 1998-06-02 | The Procter & Gamble Company | Phosphonocarboxylate compounds pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
| HUT72307A (en) * | 1993-03-08 | 1996-04-29 | Eisai Co Ltd | Phosphonic acid derivatives |
| CA2118985A1 (en) * | 1993-04-02 | 1994-10-03 | Dinesh V. Patel | Heterocyclic inhibitors of farnesyl protein transferase |
| DE69417897T2 (de) | 1993-07-09 | 1999-09-09 | Kao Corp. | 2-hydroxypropandiaminderivate und diese enthaltende detergenzzubereitung |
| US5658749A (en) * | 1994-04-05 | 1997-08-19 | Corning Clinical Laboratories, Inc. | Method for processing mycobacteria |
| JPH09316474A (ja) | 1996-05-24 | 1997-12-09 | Hitachi Maxell Ltd | 潤滑性物質およびこの潤滑性物質を用いた磁気記録媒体 |
| WO1998015525A1 (en) * | 1996-10-07 | 1998-04-16 | Sumitomo Pharmaceuticals Co., Ltd. | Hydroxamic acids |
| CA2269807C (en) | 1996-10-24 | 2007-04-10 | Novartis Ag | Substituted aminoalkanephosphonic acids |
| US6172057B1 (en) * | 1997-02-27 | 2001-01-09 | American Cyanamid Company | N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
| CA2298617A1 (en) * | 1997-07-31 | 1999-02-11 | Yetunde Olabisi Taiwo | Acyclic metalloprotease inhibitors |
| US6403632B1 (en) * | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| ZA988967B (en) * | 1997-10-03 | 2000-04-03 | Du Pont Pharm Co | Lactam metalloprotease inhibitors. |
| IT1299266B1 (it) | 1998-05-15 | 2000-02-29 | Sigma Tau Ind Farmaceuti | Inibitori reversibili della carnitina palmitoil trasferasi |
| FR2780402B1 (fr) | 1998-06-30 | 2001-04-27 | Adir | Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| TR200101663T2 (tr) | 1998-12-10 | 2001-11-21 | F.Hoffmann-La Roche Ag | Pro-kollajen c-proteinaz inhibitörleri |
| FR2788526B1 (fr) | 1999-01-20 | 2002-07-05 | Inst Nat Sante Rech Med | Composes tripeptidiques utiles a titre d'hinhibiteurs selectifs de l'aminopeptidase a et compositions pharmaceutiques correspondantes |
| EP1165500A1 (en) * | 1999-04-02 | 2002-01-02 | Du Pont Pharmaceuticals Company | Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase |
| FR2791982B1 (fr) * | 1999-04-06 | 2002-12-27 | Inst Nat Sante Rech Med | Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques. |
| AU4249700A (en) * | 1999-04-19 | 2000-11-02 | Sumitomo Pharmaceuticals Company, Limited | Hydroxamic acid derivative |
| EP1237547A2 (en) * | 1999-07-09 | 2002-09-11 | Isis Innovation Limited | Compounds for inhibiting diseases and preparing cells for transplantation |
| JP4153647B2 (ja) | 2000-04-05 | 2008-09-24 | 三菱重工業株式会社 | フェントン反応抑制剤および一重項酸素産生抑制剤 |
| DE10127922A1 (de) * | 2000-06-08 | 2001-12-13 | Jomaa Pharmaka Gmbh | Verwendung von phosphororganischen Hydroxamsäurederivaten zur Herstellung von Arzneimitteln für die therapeutische und prophylaktische Behandlung von Infektionen |
| EP1315735A4 (en) | 2000-08-31 | 2005-04-06 | Merck & Co Inc | Phosphate derivatives as immunoregulatory compounds |
| WO2002028829A2 (en) * | 2000-09-25 | 2002-04-11 | Questcor Pharmaceuticals, Inc. | Peptide deformylase inhibitors |
| US7169818B2 (en) | 2000-10-03 | 2007-01-30 | University Of Virginia Patent Foundation | Lysophosphatidic acid receptor agonists and antagonists |
| FR2816837A1 (fr) | 2000-11-17 | 2002-05-24 | Oreal | Utilisation d'au moins un derive amino sulfonique dans une composition destinee a favoriser la desquamation de la peau |
| FR2821621B1 (fr) * | 2001-03-05 | 2004-11-05 | Oreal | Polyurethannes anioniques a caractere elastique et leur utilisation dans des compositions cosmetiques |
| WO2003061567A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
| KR101076018B1 (ko) * | 2003-01-08 | 2011-10-21 | 유니버시티 오브 워싱톤 | 항균제 |
| BRPI0407658A (pt) * | 2003-02-18 | 2006-02-21 | Kyorin Seiyaku Kk | derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico |
| EP1644325A2 (en) | 2003-06-23 | 2006-04-12 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| FR2858617A1 (fr) * | 2003-08-06 | 2005-02-11 | Inst Nat Sante Rech Med | Derives de 4',4'-dithiobis-(3-aminobutane-1-sulfonate-1- sulfonates) nouveaux et compositions les contenant |
| US7662856B2 (en) * | 2003-08-29 | 2010-02-16 | The University Of Houston System | Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine |
| US20050107447A1 (en) * | 2003-11-03 | 2005-05-19 | Lynch Kevin R. | Novel lysophosphatidic acid receptor agonists and antagonists |
| JP4182910B2 (ja) | 2004-03-30 | 2008-11-19 | ダイソー株式会社 | スフィンゴミエリン類縁体とその製造法 |
| EP1828111A2 (en) * | 2004-11-12 | 2007-09-05 | Neurochem (International) Limited | Methods and fluorinated compositions for treating amyloid-related diseases |
| BRPI0519243A2 (pt) * | 2004-12-22 | 2009-01-06 | Neurochem Int Ltd | mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide |
| KR20140002082A (ko) | 2005-01-14 | 2014-01-07 | 유리젠, 인코포레이티드 | 하부 요로 장애 치료용 키트 및 개선된 조성물 |
| JP2006257069A (ja) | 2005-02-17 | 2006-09-28 | Kemikurea:Kk | 蛍光標識化スフィンゴシン１−リン酸メチレン置換体およびリン酸アルケニル置換体 |
| JP2009520695A (ja) * | 2005-12-15 | 2009-05-28 | ヴィキュロン ファーマシューティカルズ インコーポレイテッド | 抗菌活性を有するｎ−ヒドロキシアミド誘導体 |
| BRPI0819976A2 (pt) | 2007-12-03 | 2019-02-12 | Signum Biosciences, Inc. | composto mimético de ácido para a inibição de isoprenil-s-cisteinil metiltransferase, composição compreedendo os mesmos, bem como uso dos ditos compostos. |
| EP2326619B1 (en) | 2008-08-01 | 2019-02-27 | Bioxiness Pharmaceuticals, Inc. | Methionine analogs and methods of using same |
-
2009
- 2009-07-31 EP EP09791073.1A patent/EP2326619B1/en not_active Not-in-force
- 2009-07-31 WO PCT/US2009/052474 patent/WO2010014943A2/en not_active Ceased
- 2009-07-31 AU AU2009276343A patent/AU2009276343A1/en not_active Abandoned
- 2009-07-31 CN CN2009801390134A patent/CN102171185A/zh active Pending
- 2009-07-31 US US13/056,102 patent/US8580859B2/en not_active Expired - Fee Related
- 2009-07-31 CA CA2733390A patent/CA2733390A1/en not_active Abandoned
- 2009-07-31 JP JP2011521364A patent/JP5650642B2/ja not_active Expired - Fee Related
-
2011
- 2011-01-30 IL IL210956A patent/IL210956A0/en unknown
-
2013
- 2013-10-07 US US14/047,845 patent/US20140142189A1/en not_active Abandoned
-
2014
- 2014-12-10 US US14/565,970 patent/US20150329481A1/en not_active Abandoned
-
2016
- 2016-02-26 US US15/054,761 patent/US9695119B2/en not_active Expired - Fee Related
-
2017
- 2017-06-01 US US15/611,575 patent/US20170267632A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274901B2 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| JP5255456B2 (ja) | ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法 | |
| DE602004023924D1 (en) | Ease-hemmer | |
| JP2017531038A5 (https=) | ||
| WO2004113365A3 (en) | Hepatitis c serine protease tri-peptide inhibitors | |
| EP2368900A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| CA2632626C (en) | Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection | |
| EP2311851A3 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
| TW200510391A (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
| WO2008022006A3 (en) | Arylalkoxyl hepatitis c virus protease inhibitors | |
| ITMI20101459A1 (it) | Composizione comprendente glutatione reduttasi e glutatione ossidato | |
| JP2005523922A5 (https=) | ||
| MX2010006210A (es) | Inhibidores de serina proteasa de hcv de tripeptido fluorado. | |
| MY155851A (en) | Quinoxaline-containing compounds as hepatitis c virus inhibitors | |
| WO2008021871A3 (en) | Triazolyl acyclic hepatitis c serine protease inhibitors | |
| JP2013503862A5 (https=) | ||
| RU2011127079A (ru) | Комбинация производного циклоспорина и нуклеозидов для лечения инфекции вирусом гепатита с | |
| WO2001002424A3 (en) | Peptide boronic acid inhibitors of hepatitis c virus protease | |
| WO2008019266A3 (en) | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors | |
| WO2008002924A3 (en) | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors | |
| JP2011525171A5 (https=) | ||
| WO2009076166A3 (en) | Oximyl hcv serine protease inhibitors | |
| JP2005519916A5 (https=) | ||
| JP2002536452A5 (https=) | ||
| WO2008021960A3 (en) | Triazolyl macrocyclic hepatitis c serine protease inhibitors |